

Weight reduction improves markers of hepatic function and insulin resistance in type-2 diabetic patients with non-alcoholic fatty liver

Al-Jiffri O¹, Al-Sharif FM¹, *Abd El-Kader SM², Ashmawy EM²

1. Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Saudi Arabia.
2. Department of Physical Therapy, Faculty of Applied Medical Sciences, King Abdulaziz University, Saudi Arabia.

Abstract

Objective: The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing dramatically affecting up to 30% of the population worldwide. At present, treatment options are limited and pharmacological management of NAFLD has had disappointing results. Some of the best available evidence to improve NAFLD concerns lifestyle modification.

Objective: To detect the degree of weight reduction needed to improve the markers of hepatic function and insulin resistance in type-2 diabetics with NAFLD.

Methods: One hundred type-2 diabetic male patients with NAFLD were included into this study and divided into two equal groups. Group (A) received aerobic exercise training in addition to diet regimen. Group (B) received no treatment intervention.

Results: There was a 26.99%, 40.8%, 33.81%, 32.73%, 37.8% and 15 % reduction in mean values of Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma – Glutamyltransferase (GGT) and Homeostasis Model Assessment-Insulin Resistance- index (HOMA-IR) and BMI respectively in group (A) at the end of the study. While there were significant differences between mean levels of the investigated parameters in group (A) and group (B) after treatment.

Conclusion: About 15 % reduction in BMI is effective to improve the liver condition and insulin resistance in type-2 diabetics with NAFLD.

Key words: Non-alcoholic fatty liver, markers of hepatic function, insulin resistance, type-2 diabetes, weight reduction.

African Health Sciences 2013; 13(3): 667 - 672 <http://dx.doi.org/10.4314/ahs.v13i3.21>

Introduction

Nonalcoholic fatty liver disease (NAFLD) is an increasing condition associated with the sedentary lifestyle and poor nutritional habits, with high prevalence all around the World¹. NAFLD is considered the hepatic manifestation of the metabolic syndrome, a cluster of metabolic abnormalities related to insulin resistance, including central obesity and dyslipidemia². The imbalance in the metabolism of fatty acids in conjunction with the adipose tissue, liver tissue and systemic inflammation, are key factors for the development of insulin resistance, dyslipidemia and other cardiovascular risk factors

associated with the ‘nonalcoholic fatty liver disease’ (NAFLD)³.

Type 2 diabetes mellitus (T2DM) and obesity are the two metabolic conditions more closely associated with NAFLD and its progression towards advanced liver disease⁴. Paralleling the increasing prevalence of obesity, NAFLD has become common and potentially serious⁵. They both stem from alterations in insulin action (insulin resistance), a metabolic state in which physiologic concentrations of insulin produce a lower-than-normal biologic response, or higher-than-normal insulin concentrations are necessary to elicit a normal metabolic response. Thus, any measure able to modify overweight/obesity or a sedentary lifestyle, as well as the associated defect(s) in insulin action represents both a preventive measure and a treatment option for NAFLD⁶.

There is no proven treatment for patients with NAFLD are currently available. Weight reduction and lifestyle modifications with diet changes and increased physical activity are usually

*Corresponding author:

Prof. Shehab M. Abd El- Kader
Faculty of Applied Medical Sciences
Department of Physical Therapy
King Abdulaziz University
P.O. Box 80324,
Jeddah, 21589, Saudi Arabia.
Phone: +966-569849276
E. mail: salmuzain@kau.edu.sa

recommended as the first step in the treatment of patients with this condition. Achieving and maintaining weight reduction may improve NAFLD, but the results of several reports are inconsistent⁷. Studies reporting the effect of weight reduction in NAFLD to date have included small numbers of patients that were treated for a short period of time⁸.

The purpose of this study was to investigate the degree of weight reduction needed to improve the markers of hepatic function and insulin resistance in type-2 diabetic patients with NAFLD.

Methods

Subjects

One hundred type-2 diabetic male patients with NAFLD with body mass index (BMI) ranged from 30 to 35 Kg/m², their age ranged from 35 to 55 years, type 2 diabetic patients were selected according to the criteria published by the American Diabetes Association⁹, free from other liver, metabolic or genetic diseases. Participants were included in this randomized controlled study and divided into two equal groups; group (A) received physical training combined with dietary measures. The second group (B) received dietary measures only.

Participants were identified from a large number of patients attending the Liver Clinic in King Abdulaziz University Teaching Hospital, with a histological diagnosis of NAFLD. The diagnosis of NAFLD was based on the following criteria: (1) elevated aminotransferases (AST and/or ALT); (2) liver biopsy showing steatosis in at least 10% of hepatocytes; and (3) appropriate exclusion of liver disease of other aetiology including alcohol- or drug-induced liver disease, autoimmune or viral hepatitis, cholestatic or metabolic/genetic liver disease. These other liver diseases were excluded using specific clinical, biochemical, serologic tests radiographic and/or histological criteria.

Exclusion criteria included: smoking; hypertension, personal history of cardiovascular diseases, thyroid disease and orthopedic problems inhibiting treadmill training. This study was approved by the Scientific Research Ethical Committee, Faculty of Applied Sciences, King Abdulaziz University. Informed consent was obtained from all participants. All participants were free to withdraw from the study at any time. If any adverse effects had occurred, the experiment would have been stopped, with this being announced to the Human Subjects Review Board.

Chemical analysis

Blood samples were collected from the antecubital vein at the beginning and end of the treatment program. Subjects had blood drawn at the same time in the morning on each occasion (between 8 and 10 AM). Subjects lay supine for 10 min prior to the blood collection. 10 ml of blood was drawn into a tube containing few milliliters of sodium citrate; plasma was separated from the blood by centrifugation (120 × g for 15 min) at room temperature. Markers of hepatic function (aspartate aminotransferase, AST; alanine aminotransferase, ALT; alkaline phosphatase, ALP and Homeostasis Model Assessment-Insulin Resistance (HOMA) index for insulin sensitivity was computed following this equation: [fasting glycemia (mmol/L) X fasting insulin (mIU/L)]/22.5¹⁰ were measured by the colorimetric enzymatic method using an automatic spectrophotometer and respective kits for analysis (Bioclin, Quibasa, Belo Horizonte, MG, Brazil). Human insulin was measured with an insulin kit (Roche Diagnostics, Indianapolis, IN, USA) using a cobas immunoassay analyzer (Roche Diagnostics). All samples were assayed in duplicate, and the mean of the paired results was determined.

Evaluation of anthropometric parameters

All measurements were performed at pretreatment and after three months at the end of the study. The participants were measured whilst wearing their undergarments and hospital gowns. Height was measured with a digital stadiometer to the nearest 0.1 cm (JENIX DS 102, Dongsang, South Korea). Body weight was measured on a calibrated balance scale to the nearest 0.1 kg (HC4211, Cas Korea, South Korea), and BMI was calculated as BMI = Body weight / (Height)².

The physical training program

The aerobic treadmill-based training program (PRECOR 9.1/ 9.2, China) was set to 65%- 75% of the maximum heart rate (HRmax) according to a modified Bruce protocol. This rate was defined as the training heart rate (THR). After an initial, 5-minute warm-up phase performed on the treadmill at a low load, each endurance training session lasted 30 minutes and ended with 5-minute recovery and relaxation phase. All patients performed three weekly sessions (i.e. a total of 36 sessions per patient over a 3-month period).

The prescribed low calorie diet

The interview-based food survey was performed for all patients by dieticians to specify previous food habits and possible anomalies in dietary behavior. The prescribed low calorie diet was balanced, with 15% as protein, 30 to 35% as fat and 50 to 55% as carbohydrate, on average, in order to provide about 1200 Kilocalories daily for two months for whole participants in this study.

Statistical analysis

The mean values of ALP, ALT, AST, GGT, HOMA-IR and BMI obtained before and after three months in both groups were compared using paired “t” test. Independent “t” test was used for the comparison between the two groups (P<0.05).

Results

This study was an attempt to investigate the degree of weight reduction (a result that is needed to

improve the markers of hepatic function and insulin resistance in type-2 diabetic patients with NAFLD. However, no adverse effects occurred as the diet regimen was low caloric diet not a very low caloric diet and the aerobic exercise training was of moderate intensity ranged from 65%- 75% of HRmax , so the data of all the participants were available for analysis. There was a 26.99%, 40.8%, 33.81%, 32.73%, 37.8% and 15 % reduction in mean values of ALP, ALT, AST, GGT, HOMA-IR and BMI respectively in group (A) at the end of the study. The mean values of ALP, ALT, AST, GGT, HOMA-IR and BMI were significantly decreased in group received aerobic exercise training in addition to diet regimen. While the results of group (B) received no treatment intervention were not significant. Also, there were significant differences between mean levels of the investigated parameters in group (A) and group (B) after treatment (table 1, 2, 3) (P<0.05).

Table 1: Mean value and significance of the pre and post test values of ALP, ALT, AST, GGT, HOMA-IR and BMI in the training group

| | Mean + SD | | t- value | P-value |
|----------------------------|--------------|--------------|----------|---------|
| | Pre | Post | | |
| ALP (U/L) | 74.56 ± 9.32 | 58.71± 8.26 | 9.23 | 0.0015 |
| ALT (U/L) | 46.88 ± 5.41 | 33.28± 4.76 | 8.64 | 0.0013 |
| AST (U/L) | 45.98 ± 6.63 | 34.36 ± 5.11 | 9.15 | 0.0027 |
| GGT(U/L) | 28.63 ± 3.26 | 21.57 ± 3.1 | 7.34 | 0.0056 |
| HOMA-IR | 4.92 ± 2.78 | 3.57 ± 1.3 | 6.12 | 0.0083 |
| BMI (Kg / m ²) | 32.11±3.54 | 27.25 ±2.68 | 8.33 | 0.0094 |

ALT = Alanine aminotransferase GGT= Gamma – glutamyltransferase
 AST = Aspartate aminotransferase ALP = Alkaline phosphatase BMI= Body mass index
 HOMA-IR = Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) index

Table 2: Mean value and significance of the pre and post test values of ALP, ALT, AST, GGT, HOMA-IR and BMI in the control group

| | Mean + SD | | t- value | P-value |
|-----------|--------------|--------------|----------|---------|
| | Pre | Post | | |
| ALP (U/L) | 73.31 ± 8.92 | 73.68 ± 9.23 | 0.76 | 0.139 |
| ALT (U/L) | 47.22 ± 6.05 | 47.91 ± 6.75 | 0.85 | 0.144 |
| AST (U/L) | 46.16 ± 6.87 | 46.87 ± 7.24 | 0.49 | 0.172 |
| GGT(U/L) | 29.33 ± 3.76 | 30.01 ± 3.65 | 0.91 | 0.115 |
| HOMA-IR | 4.98 ± 2.51 | 5.13 ± 2.44 | 0.56 | 0.161 |
| BMI | 32.37 ± 3.92 | 32.64 ± 4.26 | 0.36 | 0.182 |

ALT = Alanine aminotransferase GGT= Gamma – glutamyltransferase
 AST = Aspartate aminotransferase ALP = Alkaline phosphatase BMI= Body mass index
 HOMA-IR = Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) index

Table 3: Mean value and significance of the post test values of ALP, ALT, AST, GGT, HOMA-IR and BMI in the training and control groups

| | Mean + SD | | t- value | P-value |
|-----------|----------------|---------------|----------|---------|
| | Training group | Control group | | |
| ALP (U/L) | 58.71± 8.26 | 73.68 ± 9.23 | 7.86 | 0.0062 |
| ALT (U/L) | 33.28± 4.76 | 47.91 ± 6.75 | 6.22 | 0.0074 |
| AST (U/L) | 34.36 ± 5.11 | 46.87 ± 7.24 | 7.07 | 0.0085 |
| GGT(U/L) | 21.57 ± 3.18 | 30.01 ± 3.65 | 5.93 | 0.0073 |
| HOMA-IR | 2.64 ± 1.37 | 5.13 ± 2.44 | 4.75 | 0.0091 |
| BMI | 27.25 ±2.68 | 32.64 ± 4.26 | 6.12 | 0.0088 |

ALT = Alanine aminotransferase GGT= Gamma – glutamyltransferase
 AST = Aspartate aminotransferase ALP = Alkaline phosphatase BMI= Body mass index
 HOMA-IR = Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) index

Discussion

As the degree and rate of weight reduction needed to improve the liver condition in patients with NAFLD remains unknown. The aim of this study was to detect the impact of weight reduction on liver enzymes and insulin resistance in type-2 diabetic patients with NAFLD received aerobic exercise training in addition to diet regimen. Based on our findings, a 15 % reduction in BMI and body weight could be recommended as an initial therapeutic target to improve the liver condition and insulin resistance in type-2 diabetic patients with NAFLD. However, the oral hypoglycemic agents who were received by participants in both groups may have some effect on insulin resistance, the more profound improvement in insulin resistance in group (A) and the little non significant changes in group (B) proved that weight reduction was of great value to enhance the therapeutic pharmacological effects of oral hypoglycemic agents. Results of this study supported with many previous studies¹¹⁻²¹.

Adherence to combined dietary restriction and increased physical activity result in larger and progressive weight loss that can be maintained through the years¹¹. Physical activity has an independent and beneficial effect on fatty liver¹². Physical exercise promotes both weight loss, by increasing the negative energy balance, and insulin sensitivity, the determinant of fatty liver, by promoting triglyceride consumption in the skeletal muscle tissue¹³. Maintaining or increasing physical activity provides health benefits for patients with fatty liver, independent of changes in weight¹⁴.

Weight, blood biochemical data as aminotransferase, albumin, cholinesterase, total cholesterol and fasting blood glucose values were significantly decreased after a program of restricted

diet and exercise (walking or jogging) for a trial period of 3 months in a previous study on twenty-five obese patients with fatty liver¹⁵.

A 10-week diet-plus-exercise and exercise-only therapeutic lifestyle programs are effective for improving anthropometric indices, insulin sensitivity, ultrasound findings and physical fitness in ultrasound-diagnosed NAFLD patients. However, the range of improvement in patients on the diet-plus-exercise program is more obvious than that in patients on the exercise-only program. Moreover, the diet-plus-exercise program resulted in significant improvement in liver biochemistry, but the exercise-only program did not. In summary, diet plus exercise is more efficacious than exercise alone in the lifestyle modification treatment of NAFLD¹⁶.

In general, weight loss was shown to improve liver histology¹⁷, whereas gradual weight reduction and increased physical activity improves liver enzymes^{15, 18}, insulin sensitivity and quality of life¹⁹. In T2DM patients, moderate weight reduction (8%) was shown to reduce liver fat that was accompanied by a dramatic improvement in hepatic insulin resistance, with return to normal suppression of hepatic glucose production by insulin²⁰.

Regular exercise was also associated with significantly greater ALT improvement and normalization. For instance, exercise is known to improve the sensitivity of muscle mass to insulin²¹. Furthermore, exercise that was not enough to reduce body weight showed modest therapeutic effect in reducing visceral fat and improving glucose intolerance²².

Energy restriction resulting in even modest weight loss suppresses endogenous cholesterol synthesis which leads to a decline in circulating lipid

concentrations and increased insulin sensitivity that contributes in improving lipoprotein profile after treatment of obesity^{23,24}. Low carbohydrate diet and a low fat-diet may be useful in reducing the intrahepatic triglyceride content^{25,26}. Furthermore, 5% or greater weight reduction was associated with decrease in serum triglycerides, increase in serum HDL-cholesterol and decrease in fasting blood glucose. This indicates that achieving and maintaining 5% weight reduction will improve not only the liver condition but also several other components of the metabolic (insulin resistance) syndrome¹⁸.

Conclusion

Based on our findings, a 15 % reduction in BMI is effective to improve the liver condition and insulin resistance in type-2 diabetic patients with NAFLD to improve the liver condition.

Acknowledgment

This project was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant no. (49/142/1432). The authors, therefore, acknowledge with thanks DSR technical and financial support.

References

1. Fan J, Farrell G. Epidemiology of non-alcoholic fatty liver disease in China. *J Hepatol* 2009; 50: 204–210.
2. Angulo P. Nonalcoholic fatty liver disease. *N Engl J Med* 2002; 346: 1221–1231.
3. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. *Hepatology* 2010; 51: 679–689.
4. Marchesini G, Bugianesi E, Forlani G. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *Hepatology* 2003; 37: 917–923.
5. Ito O, Muroya Y, Mori N, Nagasaka M, Kanazawa M, Kohzuki M. Poster 232: Improvement of Pediatric Nonalcoholic Fatty Liver Disease by Diet and Physical Exercise: A Case Report. *Arch Phys Med Rehabil* 2007; 88 (9): E76
6. Targher G, Bellis A, Fornengo P, Ciaravella F, Pichiri I, Perin P, et al. Prevention and treatment of nonalcoholic fatty liver disease. *Dig Liver Dis* 2010; 42(5): 331-340.

7. Andersen T, Gluud C, Franzmann M, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. *J Hepatol* 1991; 12: 224–229.
8. Wang R, Koretz R, Yee H. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. *Am J Med* 2003; 115: 554–559.
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2008;31(Suppl. 1):S55–60.
10. Wilund KR. Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease? *Clin Sci (Lond)* 2007; 112(11):543-55.
11. Saris W, Blair S, van Baak M. How much physical activity is enough to prevent unhealthy weight gain? Outcome of the IASO 1st Stock Conference and consensus statement. *Obes Rev* 2003; 4:101–114.
12. Cox K, Burke V, Morton A. Independent and additive effects of energy restriction and exercise on glucose and insulin concentrations in sedentary overweight men. *Am J Clin Nutr* 2004; 80: 308–316.
13. Kantartzis K, Thamer C, Peter A. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. *Gut* 2009; 58: 1281–1288.
14. St George A, Bauman A, Johnston A. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. *Hepatology* 2009; 50: 68–76.
15. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. *Journal of Hepatology*. 1997; 27, (1):103-107.
16. Chen S, Liu C, Li S, Huang H, Tsai C, Jou H. Effects of Therapeutic Lifestyle Program on Ultrasound-diagnosed Nonalcoholic Fatty Liver Disease. *Journal of the Chinese Medical Association* 2008; 71(11):551-558.
17. Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease. *Nat Clin Pract Gastroenterol Hepatol* 2005; 2:148–155.
18. Suzuki A, Lindor K, St Saver J, Lymp J, Mendes F, Muto A, Okada T, Angulo P. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. *Journal of Hepatology* 2005; 43(6):1060-1066

19. Hickman I, Jonsson J, Prins J. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. *Gut* 2004; 53: 413–419.
20. Petersen K, Dufour S, Befroy D. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. *Diabetes* 2005; 54: 603–608.
21. Perseghin G, Price T, Petersen K, Roden M, Cline G, Gerow K. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. *N Engl J Med* 1996; 335: 1357–1362.
22. Ross R, Dagnone D, Jones P, Smith H, Paddags A, Hudson R. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized controlled trial. *Ann Intern Med* 2000; 133: 92–103.
23. Di Buono, M, Hannah JS, Katzel LL, Jones PJ. Weight loss due to energy restriction suppresses cholesterol biosynthesis in overweight, mildly hypercholesterolemic men. *J Nutr* 1999; 129 (8): 1545 – 8.
24. Lamarche B, Despres J, Pouliot MC, Moorjani S, Lupien P, Jheriault G, Tremblay A, Nadeau A, Bouchard C. Is body fat loss a determinant factor in the improvement of carbohydrate and lipid metabolism following aerobic exercise training in obese women?. *Metabolism* 1992; 41 (11): 1249-1256.
25. Browning J, Davis J, Saboorian M. A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content. *Hepatology* 2006; 44: 487–488.
26. Weaterbacka J, Lammi K, Hakkinen A. Dietary fat content modifies liver fat in overweight non-diabetic subjects. *J Clin Endocrinol Metab* 2005; 90:2804-2809.